Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile
Dana-Farber’s Breast Oncology Center

@dfci_breastonc

Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425

ID: 1491159909794291720

linkhttps://www.dana-farber.org/breast-oncology-program/ calendar_today08-02-2022 21:20:39

4,4K Tweet

5,5K Followers

348 Following

Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo
Dana-Farber’s Breast Oncology Center
@dfci_breastonc

a month ago

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉pubmed.ncbi.nlm.nih.gov/38935923/ Paolo Tarantino Sara Tolaney Nabihah Tayob Ada Waks Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉pubmed.ncbi.nlm.nih.gov/38935923/ <a href="/PTarantinoMD/">Paolo Tarantino</a> <a href="/stolaney1/">Sara Tolaney</a> <a href="/NabihahTayob/">Nabihah Tayob</a> <a href="/adawaksmd/">Ada Waks</a> <a href="/awolff/">Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)</a>